Homoleptic Phosphino Copper(I) Complexes with in Vitro and in Vivo Dual Cytotoxic and Anti-angiogenic Activity
Overview
Affiliations
Homoleptic, tetrahedral Cu(i) complexes of the type [Cu(P)4]BF4 (1-3), where P are the phosphine ligands, 1,3,5-triaza-7-phosphaadamantane (PTA), 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (DAPTA) and 2-thia-1,3,5-triaza-phosphoaadamantane-2,2-dioxide (PTA-SO2), have been prepared. Novel complexes [Cu(DAPTA)4]BF42 and [Cu(PTA-SO2)4]BF43 have been fully characterized by means of spectroscopic methods, corroborated by XAS-EXAFS analysis of 2. In vitro cell culture experiments revealed a significant antiproliferative activity for Cu(i) compounds against several human cancer cell lines derived from solid tumors with preferential cell growth inhibition towards tumour compared to non-malignant cells. In vitro monitoring of migration and capillary-like tube formation of human umbilical vein endothelial cells (HUVECs) showed an anti-angiogenic effect of copper(i) complexes at sub-cytotoxic concentrations. In vivo studies on the antitumor efficacy and ability to inhibit angiogenesis confirmed the dual cytotoxic and anti-angiogenic properties of Cu(i) derivatives.
Maged A, Mabrouk M, Nour El-Din H, Osama L, Badr-Eldin S, Mahmoud A Front Pharmacol. 2024; 15:1397639.
PMID: 38895619 PMC: 11183308. DOI: 10.3389/fphar.2024.1397639.
Heuberger D, Wolint P, Jang J, Itani S, Jungraithmayr W, Waschkies C Cancers (Basel). 2022; 14(20).
PMID: 36291910 PMC: 9600560. DOI: 10.3390/cancers14205122.
Pivovarova E, Climova A, Swiatkowski M, Staszewski M, Walczynski K, Dziegielewski M Int J Mol Sci. 2022; 23(17).
PMID: 36077257 PMC: 9456159. DOI: 10.3390/ijms23179844.
Pellei M, Santini C, Bagnarelli L, Battocchio C, Iucci G, Venditti I Int J Mol Sci. 2022; 23(16).
PMID: 36012662 PMC: 9409343. DOI: 10.3390/ijms23169397.
Mahendiran D, Amuthakala S, Bhuvanesh N, Senthil Kumar R, Rahiman A RSC Adv. 2022; 8(30):16973-16990.
PMID: 35540520 PMC: 9080330. DOI: 10.1039/c8ra00954f.